Sarpogrelate: cardiovascular and renal clinical potential

Bibliography

• DOGGRELL SA: The role of 5-HT on the cardiovascular and renal systems and clinical potential of 5-HT modulation. Expert Opin. Investig. Drugs (2003) 12:805–823.
   PubMed Web of Science ®Google Scholar
• HAMAMORI Y, YOKOYAMA M, YAMADA M et al.: 5-Hydroytryptamine induced phospholipase C-mediated hydrolysis of phosphoinositides through 5-hydroxytryptamine receptors in cultures fetal mouse ventricular myocytes. Circ. Res. (1990) 66:1474–1483.
   PubMed Web of Science ®Google Scholar
• LAER S, REMMERS F, SCHOLZ H et al: Receptor mechanisms involved in the 5-HT-induced inotropic action in the rat isolated atrium. Br. J. Pharmacol (1998) 123:1182–1188.
   PubMed Web of Science ®Google Scholar
• KAUMANN AJ, SANDERS L, BROWN AM, MURRAY KJ, BROWN MJ: A 5-hydroxytryptamine receptor in human atrium. Br. J. Pharmacol (1990) 100:879–885.
   PubMed Web of Science ®Google Scholar
• NILSSON T, LONGMORE H, SHAW D et al. Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. Eur: Pharmacol (1999) 372:49–56.
   PubMed Web of Science ®Google Scholar
• GOLINO P, PISCIONE F, WILLERSON JT et al. Divergent effects of serotonin in coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl. J. Med. (1991) 324:641–648.
   PubMed Web of Science ®Google Scholar
• LEOSCO D, FINESCHI M, PIERLI C et al.: Intracoronary serotonin release after high-pressure coronary stenting. Jim. I Cardiol (1999) 84:1317–1322.
   Google Scholar
• WRIGHT L, HOMANS DC, LAXSON DD, DAI XZ, BACHE RJ: Effect of serotonin and thromboxane A2 on blood flow through moderately well developed coronary collateral vessels.' Am. Coll. Cardiol (1992) 19:687–693.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, KLEIN W, TIJSSEN JP et al.: Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A muticenter randomized double-blind placebo-controlled trial. Circulation (1993) 88:1588–1601.
   PubMed Web of Science ®Google Scholar
• LEE SL, WANG WW, MOORE BJ, FANBURG BL: Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ. Res. (1991) 68:1362–1368.
   PubMed Web of Science ®Google Scholar
• PAKALA R, WILLERSON JT, BENEDICT CR: Mitogenic effect of serotonin on vascular endothelial cells. Circulation (1994) 90:1919–1926.
   PubMed Web of Science ®Google Scholar
• DOGGRELL SA: Pharmacotherapy of intermittent claudication. Expert Opin. Pharmacother: (2001) 2:1725–1736.
   Google Scholar
• SMULDERS YM: Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction. Cardiovasc. Res. (2000) 48:23–33.
   PubMed Web of Science ®Google Scholar
• STEYN DW, ODENDAAL HJ: Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia. Lancet (1997) 350:1267–1271.
   PubMed Web of Science ®Google Scholar
• BARRADAS MA, GILL DS, FONSECA VA, MIKHAILIDIS DP, DANDONA R: Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur: Clin. Invest (1988) 18:399–404.
   PubMed Web of Science ®Google Scholar
• MALYSZKO H, URANO T, KNOFLER R et al.: Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb. Res. (1994) 75:569–576.
   PubMed Web of Science ®Google Scholar
• RATTIGAN S, DORA KA, COLQUHOUN EQ, CLARK MG: Serotonin-mediated acute insulin resistance in the perfused rat hindlimb but not in incubated muscle: a role for the vascular system. Life Sci. (1993) 53:1545–1555.
   PubMed Web of Science ®Google Scholar
• HEAD RJ, LONGHURST PA, PANEK RL, STITZEL RE: A contrasting effect of the diabetic state upon the contractile responses of aortic preparations from the rat and rabbit. Br. J. Pharmacol (1987) 91:275–286.
   PubMed Web of Science ®Google Scholar
• JAMES GM, HODGSON WC: Attenuated 5-HT2 receptor-mediated responses in hindquarters of diabetic rats. Eur. Pharmacol (1995) 294:109–115.
   PubMed Web of Science ®Google Scholar
• TURNER NC, WHITE P: Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinaemic obese Zucker rats. J. Cardiovasc. Pharmacol (1996) 27:884–890.
   PubMed Web of Science ®Google Scholar
• EL-KASHEF H: Hyperglycemia increased the responsiveness of isolated rabbit pulmonary arterial rings to serotonin. Pharmacology (1996) 53:151–159.
   PubMed Web of Science ®Google Scholar
• BEENEN OH, MATHY MJ, PFAFFENDORF M, VAN ZWEITEN PA: Vascular responsiveness in isolated perfused kidneys of diabetic hypertensive rats. Hypertens. (1996) 14:1125–1130.
   Web of Science ®Google Scholar
• BOSTON PC, HODGSON WC: Changes in reactivity toward 5-hydroxytryptamine in the renal vasculature of the diabetic spontaneoulsy hypertensive rat." Hypertens. (1997) 15:769–774
   PubMed Web of Science ®Google Scholar
• MIRANDA FJ, ALABADI JA, LLORENS S et al.: Experimental diabetes induces hyperreactivity of rabbit renal artery to 5-hydroxytryptamine. Eur: j Pharmacol (2002) 439:121–127.
   PubMed Web of Science ®Google Scholar
• WEBSTER GJ, PETCH EW, COWEN T: Streptozotocin-induced diabetes in rats causes neuronal deficits in tyrosine hydroxylase and 5-hydroxytryptamine specific to mesenteric perivascular sympathetic nerves and without loss of nerve fibers. Exp. Neural. (1991) 113:53–62.
   PubMed Web of Science ®Google Scholar
• KASHO M, SAKAI M, SASAHARA T et al.: Serotonin enhances production of type IV collagen by human mesangial cells. Kidney Int. (1998) 54:1083–1092.
   PubMed Web of Science ®Google Scholar
• KIKUMOTO R, HARA H, NINOMIYA K et al.: Synthesis and platelet aggregation inhibitory and antithrombotic properties of [2[(omega-aminoalkpxy)phenyl]ethyl]benzenes. Med. Chem. (1990) 33:1818–1823.
   Web of Science ®Google Scholar
• •Initial description of sarpogrelate.
   Google Scholar
• MARUYAMA K, KINAMI J, SUGITA Y et al.: MCI-9042: high affinity for serotonergic receptors as assessed by radioligand binding assay. Pharmacobiodyn. (1991) 14:177–181.
   PubMedGoogle Scholar
• HARA H, OSAKABE M, KITAJIMA A, TAMAO Y, KIKUMOTO R: MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb. Haemost. (1991) 65:415–420.
   PubMed Web of Science ®Google Scholar
• PERTZ H, ELZ S: In-vitro pharmacology of sarpogrelate and enantiomers of its major metabolite: 5-HT2A receptor specificity, stereoselectivity and modulation of ritanserin-induced depression of 5-HT contraction in rat tail artery. Pharm. Pharmacol (1995) 47:310–316.
   PubMed Web of Science ®Google Scholar
• ••Important characterisation of the receptoreffects of sarpogrelate and its metabolite.
   Google Scholar
• NISHIO H, INOUE A, NAKATA Y: Binding affinity of sarpogrelate, a new antiplatelet agent, and metabolite for serotonin receptor subtypes. Arch. Int. Pharmacodyn. Ther. (1996) 331:189–202.
   PubMedGoogle Scholar
• ISRAILOVA M, SUZUKI F, TANAKA T et al.: Binding and functional affinity of sarpogrelate, it metabolite M-1 and ketanserin for human recombinant a-1-adrenoceptor subtypes. Pharmacology (2002) 65:69–73.
   PubMed Web of Science ®Google Scholar
• NISHIO H, YOSHIKAWA S, MORIMOTO Y, CHEN Z, NAKATA Y: Binding affinity of sarpogrelate to 5-HT2A receptor ligand recognition sites in rat renal cortical and mesangial cells in culture. Gen. Pharmacol (1999) 33:51–57.
   PubMedGoogle Scholar
• NAKAMURA K, KARIYAZONO H, MORIYAMA Y et al: Effects of sarpogrelate hydrochloride on platelet aggregation and its relation to the release of serotonin and P-selectin. Blood Cavil]. Fibrinolysis (1999) 10:513–519.
   PubMed Web of Science ®Google Scholar
• QI R, OZAKI Y, SATOH K et al: Quantitative measurement of various 5-HT receptor antagonists on platelet activation induced by serotonin. Thromb. Res. (1996) 81:43–54.
   PubMed Web of Science ®Google Scholar
• NAKAMURA K, KARIYAZONO H, MASUDA H, SAKATA R, YAMADA K: Effects of sarpogrelate hydrochloride on adenosine or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis. (2001) 12:391–397.
   PubMed Web of Science ®Google Scholar
• PIETRASZEK MH, TAKADA Y, TAMINATO A et al.: The effect of MCI-9042 on serotonin-induced platelet aggregation in Type 2 diabetes mellitus. Thromb. Res. (1993) 70:131–138.
   PubMed Web of Science ®Google Scholar
• SHOUZU A, NOMURA S, HAYAKAWA T et al.: Effect of sarpogrelate hydrochloride on platelet-derived microparticles ans various soluble adhesion molecules in diabetes mellitus. Gin. Appl. Thromb. Hemost. (2000) 6:139–143.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, ZAHRADKA P, CHAPMAN D et al.: Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. Pharmacol Exp. Ther. (1999) 290:1475–1481.
   PubMed Web of Science ®Google Scholar
• WATANABE T, PAKALA R, KATAGIRI T,BENEDICT CR: Angiotensin II and serotonin potentiate endothelin-l-induced vascular smooth muscle cell proliferation. Hypertens. (2001) 19:731–739.
   Web of Science ®Google Scholar
• WATANABE T, PAKALA R, KATAGIRIT, BENEDICT CR: Monocyte chemotactic protein 1 amplifies serotonin-induced vascular smooth muscle cell proliferation. Vasc. Res. (2001) 38:341–349.
   PubMed Web of Science ®Google Scholar
• SHARMA SK, DEL RIZZO DF, ZAHRADKA P et al.: Sarpogrelate inhibits serotonin-induced proliferation of porcine coronary artery smooth muscle cells: implications for long-term graft patency. Ann. Thome. Surg. (2001) 71:1856–1864.
   PubMed Web of Science ®Google Scholar
• IKEDA K, TOJO K, TOKUDOME G et al.: The effects of sarpogrelate on cardiomyocyte hypertrophy. Life ScL 67:2991-2996.
   Google Scholar
• ETO Y, NITTA K, UCHIDA K et al.: Anti-mitogenic effects of sarpogrelate in cultured rat mesangial cells. Life ScL (1997) 60:PL193-PL199.
   Google Scholar
• KASHO M, SAKAI M, SASAHARA T et al.: Serotonin enhances the production of Type IV collagen by human mesangial cells. Kidney Int. (1998) 54:1083–1092.
   PubMed Web of Science ®Google Scholar
• MIKAWA K, AKAMATSU H, NISHINA K et al: The effects of sarpogrelate on superoxide production by human neutrophils. Reg. Anesth. Pain. Med. (2000) 25:181–185.
   PubMed Web of Science ®Google Scholar
• HARA H, KITAJIMA A, SHIMADA H, TAMAO Y: Antithrombotic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb. Haemost. (1991) 66:484–488.
   PubMed Web of Science ®Google Scholar
• KIHARA H, KOGANEI H, HIROSE K, YAMAMOTO H, YOSHIMOTO R: Antithrombotic activity of AT-1015, a potent 5-HT2A receptor antagonist, in rat arterial thrombosis model and its effect on bleeding time. Ear: JPharmacol. (2001) 433:157–162.
   PubMed Web of Science ®Google Scholar
• MIYATA K, SHIMOKAWA H, HIGO T et al.: Sarpogrelate, a selective 5-HT2A serotonergic receptor antagonist, inhibits serotonin-induced coronary artery spasm in a porcine model. Cardiovasc. Pharmacol (2000) 35:294–301.
   PubMed Web of Science ®Google Scholar
• HAYASHI T, SUMI D, MATSUI-HIRAI H et al.: Sarpogrelate HC1, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis (2003) 168:23–31.
   PubMed Web of Science ®Google Scholar
• ORIGUCHI N, SHIGEMATSU H, MUTO T: Anplag, a selective 5-HT2 receptor antagonist, reduces stenosis induced by balloon injury in the hypercholesterolaemic rabbit. Int. Angiol (1997) 16:204–209.
   PubMed Web of Science ®Google Scholar
• HARA H, SHIMADA H, KITAJIMA A, TAMAO Y: Effect of (+/-)-2-(dimethylamino)-1- methoxyphenethyl) phenoxy] methyl]ethyl hydrogen succinate on experimental models of peripheral obstructive disease. Arzneimittelforschung (1991) 41:616–620.
   PubMed Web of Science ®Google Scholar
• MIYATA M, ITO M, SASAJIMA T et al.:Development of monocrotaline-induced pulmonary hypertension is attenuated by a serotonin receptor antagonist. Lung (2000) 178:63–73.
   PubMed Web of Science ®Google Scholar
• HIRONAKA E, HONGO M, SAKAI A et al.: Serotonin receptor antagonist inhibits monocrotaline-induced pulmonary hypertension and prolongs survival in rats. Cardiovasc. Res. (2003) 60:692–629.
   PubMed Web of Science ®Google Scholar
• MIYATA M, ITO M, SASAJIMA T, OHIRA H, KASUKAWA R: Effect of a serotonin receptor antagonist on interleukin-6-induced pulmonary hypertension in rats. Chest (2001) 119:554–561.
   PubMed Web of Science ®Google Scholar
• SETOGUCHI Y, OHNUKI T, RASKID M et al.: Effects of chronic administration of sarpogrelate on systolic blood pressure of spontaneously hypertensive rats: comparison with quinapril. Pharmacol (2002) 64:71–75.
   PubMed Web of Science ®Google Scholar
• TEMSAH RM, KUMAMOTO H, TAKEDA N, DHALLA NS: Sarpogrelate diminishes changes in energy stores and ultrastructure of the ischemic-reperfused rat heart. Can. Physiol Pharmacol (2001) 79:761–767.
   PubMed Web of Science ®Google Scholar
• BRASIL D, TEMSAH RM, KUMAR K: Blockade of 5-HT 2A receptors by sarpogrelate protects the heart against myocardial infarction in rats.' Cardiovasc. Pharmacol Ther. (2002) 7:53–59.
   PubMedGoogle Scholar
• SHIMIZU Y, MINATOGUCHI S, HASHIMOTO K et al.: The role of serotonin in ischemic cellular damage and the infarct size-reducing effect of sarpogrelate, a 5-hydroxytryptamine-2A receptor blocker, in rabbit hearts. .1 Am. Coll. Cardiol (2002) 40:1347–1355.
   Google Scholar
• ICHIYANAGI N, TSUJII T, MASUDA H et al.: Changes responsiveness of the detrusor in rabbits with alloxan induced hyperglycemia: possible role of 5-hydroxytryptamine for diabetic bladder dysfunction. .1 Urn] (2002) 168:303–307.
   Google Scholar
• UMRANI DN, BODIWALA DN, GOYAL RK: Effect of sarpogrelate on altered STZ-diabetes induced cardiovascular responses to 5-hydroxytryptamine in rats. Ma Cell. Biochem. (2003) 249:53–57.
   PubMed Web of Science ®Google Scholar
• CAMERON NE, COTTER MA: The effect of 5-hydoxytryptamine 5-HT2 receptor antagonists on nerve conduction velocity and endoneurial perfusion in diabetic rats. Naunyn Schnnedebergs Arch. Pharmacol (2002) 367:607–614.
   Web of Science ®Google Scholar
• TAKISHITA E, TAKAHASHI A, HARADA N et al.: Effect of sarpogrelate, a 5-HT2 blocker, on insulin resistance in Otsuka Long-Evans Tokushima fatty rats (OLETF rats), a Type 2 diabetic rat model. Cardiovasc. Pharmacol (2004) 43:266–270.
   PubMed Web of Science ®Google Scholar
• KANAI H, HIROMURA K, KUROIWA T et al.: Role of serotonin in nephrotoxic serum nephritis in WKY rats. I Lab. Clin. Med. (1997) 129:557–566.
   PubMedGoogle Scholar
• TANAKA T, FUJITA M, NAKAE I et al.: Improvement of exercise capacity by sarpogrelate as a result of augmented collateral circulation in patients with effort angina. I Am. Coll. Cardiol (1998) 32:1982–1986.
   PubMed Web of Science ®Google Scholar
• KINUGAWA T, FUJITA M, LEE JD et al: Effectiveness of a novel serotonin blocker, sarpogrelate, for patients with anginal pectoris. Am. Heart. (2002) 144:E1
   Google Scholar
• SATOMURA K, TAKASE B, HAMABE A et al.: Sarpogrelate, a specific 5-HT2-receptor antagonist, improves coronary microcirculation in coronary artery disease. Clin. Cardiol (2002) 25:28–32.
   PubMed Web of Science ®Google Scholar
• HORIBE E, NISHIGAKI K, MINATOGUCHI S, FUJIWARA H: Sarpogrelate, a 5-HT2 receptor blocker, may have a preconditioning-like effect in patients with coronary artery disease. Circ. J. (2004) 68:68–72.
   PubMed Web of Science ®Google Scholar
• FUJITA M, MIZUNO K, HO M et al.: Sarpogrelate treatment reduces restenosis after coronary stenting. Am. Heart. (2003) 145:E16.
   PubMedGoogle Scholar
• USUI A, TAKAGI Y, OHARA Y et al: Sarpogrelate reduces mechanical hemolysis in patients with heart valve prostheses. fpn Thome. Cardiovasc. &mg. (2000) 48:769–774.
   Google Scholar
• ISHIMURA E, NICHIZAWA Y, EMOTO M et al.: Therapeutic effect of sarpogrelate, a new 5-hydroxytryptamine receptor 2A antagonist, in diabetic nephropathy and neuropathy. Nephron (1997) 76:227–229.
   PubMedGoogle Scholar
• OGAWA S, TAKEUCHI K, SUGIMURA K et al.: The 5-HT2 receptor antagonist sarpogrelate reduces urinary and plasma levels of thromboxane A2 and urinary albumin excretion in non-insulin-dependent diabetes mellitus patients. Clin. Exp. Pharmacol Physiol (1999) 26:461–464.
   PubMed Web of Science ®Google Scholar
• TAKAHASHI T, YANO M, MINAMI J et al.: Sarpogrelate hydrochloride, a serotonin2A receptor antagonist reduces albuminuria in diabetic patients with early-stage diabetic nephropathy. Diabetes Res. Clin. Piaci (2002) 58:123–129.
   PubMed Web of Science ®Google Scholar
• IGARASHI M, OKUDA T, OH-IT, KOGA M: Changes in plasma serotonin concentration and acceleration plethysmograms in patients with Raynaud's phenomenon after long-term treatment with a 5-HT2 receptor antagonist. Dermatol (2000) 27:643–650.
   Google Scholar
• KATO S, KISHIRO I, MACHIDA M et al.: Suppressive effect of sarpogrelate hydrochloride on respiratory failure and right ventricular failure with pulmonary hypertension in patients with systemic sclerosis. Int. Med. Res. (2000) 28:258–268.
   PubMed Web of Science ®Google Scholar
• RYDZEWSKI A, URANO T, HACHIYA T et al.: The effect of a 5-HT2 antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb. Res. (1996) 84:445-452. Website
   Google Scholar
• http://www.who.int/medicines/library/ pnewslet/npn0101.html WHO Pharmaceuticals newsletter (2001).
   Google Scholar